Education
About Us
Working with TipRanks
Follow Us
Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 75.62M | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 67.50M | $ -6.22M | $ -8.56M | $ 0.00 | $ -537.00K |
| Operating Income | $ -81.11M | $ -143.31M | $ -112.38M | $ -72.88M | $ -28.01M |
| EBITDA | $ -72.99M | $ -137.09M | $ -108.64M | $ -70.75M | $ -27.47M |
| Net Income | $ -72.70M | $ -135.35M | $ -108.50M | $ -73.96M | $ -35.88M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 372.15M | $ 232.41M | $ 262.83M | $ 346.07M | $ 41.70M |
| Total Assets | $ 438.73M | $ 303.75M | $ 342.39M | $ 366.33M | $ 49.38M |
| Total Debt | $ 42.72M | $ 46.04M | $ 47.00M | $ 0.00 | $ 67.76M |
| Net Debt | $ -181.54M | $ -82.06M | $ -7.91M | $ -346.07M | $ 26.07M |
| Total Liabilities | $ 215.80M | $ 124.50M | $ 70.98M | $ 18.81M | $ 98.11M |
| Stockholders' Equity | $ 222.94M | $ 179.25M | $ 271.41M | $ 347.51M | $ -48.73M |
| Cash Flow | |||||
| Free Cash Flow | $ 38.01M | $ -62.84M | $ -105.38M | $ -69.09M | $ -26.44M |
| Operating Cash Flow | $ 42.00M | $ -43.80M | $ -92.47M | $ -59.36M | $ -23.05M |
| Investing Cash Flow | $ -44.45M | $ 88.80M | $ -219.22M | $ -9.65M | $ -3.39M |
| Financing Cash Flow | $ 98.89M | $ 27.49M | $ 20.47M | $ 377.56M | $ 60.06M |